On September 29, the last exemption runs out. A 100 percent tariff on imported patented medicines and their active ingredients applies to every remaining company shipping them into the United States.
Here is what the headline number hides. By that date, 26 drugmakers had already signed pricing agreements with the administration that set their tariff rate at zero. The White House says those companies cover roughly 90 percent of the branded pharmaceutical market.
So the 100 percent rate is real, and it is also the rate almost nobody at the top of the industry will pay. Working out who does pay, and whether any of it reaches your pharmacy counter, takes about five minutes.
What the April Proclamation Actually Did
The legal instrument is a presidential proclamation signed on April 2, 2026, issued under Section 232 of the Trade Expansion Act of 1962. That statute lets a president adjust imports the Commerce Department finds to be a national security threat.
Commerce made that finding for medicines. The proclamation cites Food and Drug Administration data from 2025 showing that about 53 percent of patented pharmaceutical products distributed in the United States are made abroad. For the active ingredients inside those drugs, the domestic share is far smaller: only 15 percent by volume.
The proclamation set two effective dates. Companies named in its Annex III started paying on July 31, 2026. Everyone else starts on September 29. That second date is the one still ahead.
Section 232 has become the administration’s workhorse after courts narrowed other tariff powers, a pattern we traced in Trump’s tariff playbook and how each legal setback fuels the next trade move.
Five Rates, and the Headline One Is the Rarest
Read past the proclamation’s first paragraph and a tiered structure appears. Your rate depends on three things: which company owns the product, where it was made, and what kind of medicine it is.
| Situation | Rate |
|---|---|
| Default for patented drugs and ingredients listed in Annex I | 100% |
| Company holds a Commerce-approved onshoring plan | 20%, rising to 100% on April 2, 2030 |
| Products of the EU, Japan, South Korea, Switzerland and Liechtenstein | 15% |
| Products of the United Kingdom | 10%, reducible to zero under a future pricing deal |
| Company holds a most-favored-nation pricing agreement and is onshoring-eligible | 0% until January 20, 2029 |
| Orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, CBRN countermeasures, animal health products (conditions apply) | 0% |
| Generic medicines and biosimilars | Not covered at this time |
| US-origin pharmaceutical products | Not covered |
Two technical rules change the arithmetic more than most summaries admit. First, for the main rates the Section 232 duty does not stack on top of the normal tariff. It is set so the combined total equals the listed rate. Second, where more than one rate could apply, the lowest one wins.
Why the Biggest Brands Are Already Out
The exemption route runs through drug pricing, not trade policy. Beginning with Pfizer in September 2025, drugmakers have been signing bilateral agreements with the Commerce Department and the Department of Health and Human Services. The template is consistent: most-favored-nation pricing for state Medicaid programs, MFN pricing on newly launched medicines, participation in the government’s TrumpRx.gov direct-to-consumer platform, and commitments to build manufacturing capacity in the United States.
In exchange, signatories get a multi-year suspension of the pharmaceutical tariff.
The pace accelerated through 2026. TrumpRx.gov went live on February 5. On August 31, the White House announced agreements with nine mid-sized manufacturers, bringing the total to 26 companies.
Two caveats belong here. The agreements are voluntary and their specific pricing terms are confidential, so their real effect on what patients pay is hard to measure from outside. And they do not require companies to cut list prices on medicines already on the market. The industry group PhRMA has argued that most-favored-nation pricing is not the most effective route to lower costs and has pointed instead at pharmacy benefit managers. Both positions remain contested.
So Who Actually Pays on September 29?
Four groups are left holding the bill.
- Smaller innovator companies without an agreement. The 26 signatories are large and mid-sized firms. Below that tier sit hundreds of specialty and biotech companies with patented products and no deal.
- Manufacturers outside the named country tiers. A patented drug made in India, Canada, Australia or China falls to the 100 percent default, because those origins are not in the 15 percent or 10 percent groups.
- Contract manufacturers and ingredient suppliers. Active pharmaceutical ingredients and key starting materials are covered by Annex I in their own right, not only as part of a finished drug.
- Importers of record. The duty is owed at the border by the importer, whatever the arrangement with the overseas seller.
That last point is the one businesses most often get wrong. Tariffs are not paid by foreign governments or foreign factories. They are paid by whoever brings the goods in, which is why sector-specific duties so often land somewhere other than their stated target — a dynamic we examined in the case of tariffs on the Gulf shrimp trade.
The Generic Clock Is Where Prices Actually Live
Now the part that matters most for household budgets, and that most coverage of the September 29 date skips.
According to the FDA, nine out of ten prescriptions filled in the United States are for generic medicines. The Association for Accessible Medicines puts 2024 numbers on that split: generics accounted for 90 percent of prescriptions but only 12 percent of prescription spending, while branded drugs made up 10 percent of prescriptions and 88 percent of the money.
The April proclamation excluded generics and biosimilars entirely. It also directed Commerce to report back within a year on whether that should change.
It changed sooner. On July 21, 2026, President Trump announced on Truth Social that imported generics would stay duty-free for two years from August 1, 2026, then face a 100 percent tariff for one year from August 2028, rising to 200 percent from August 2029. He framed it as a penalty for companies that decline to build US plants.
Two qualifications are worth stating plainly. This was a social media announcement, not a proclamation, and the implementation detail — how finished doses versus ingredients would be treated, what exemptions might apply — has not been published. Until it is, the generic timeline is a stated intention rather than a rule in force.
The exposure, though, is easy to size. Research from the IQVIA Institute found Indian companies supplied 47 percent of all generic prescriptions filled in the United States, the largest single source. Indian pharmaceutical stocks fell the day after the announcement.
What This Means for What You Pay
Set expectations correctly for the September date.
Most branded medicines you are likely to be prescribed come from companies that now sit in the zero or reduced tiers. The tariff does not touch them directly this month. Where it can bite is narrower: specialty and niche branded drugs from smaller manufacturers, and products whose active ingredients come from countries in the default tier.
Even then, a tariff at the border does not translate one-for-one into a pharmacy price. Rebate contracts, pharmacy benefit manager arrangements, insurance design and formulary decisions all sit between the two. The gap between what a medicine costs to import and what a patient is charged is wide and opaque, which is a large part of why the same therapy can carry radically different prices across countries — a pattern visible in the price gap driving cancer patients toward CAR-T treatment abroad.
The date to mark is not September 29. It is August 2028, when the generic tariff is scheduled to begin, because that is the segment covering nine of every ten prescriptions.
A Pre-Deadline Checklist for Importers
If your business brings covered products into the United States, five checks are worth completing before the end of September.
- Classify the product. Confirm whether your HTSUS codes appear in Annex I, and check Annex IV, which lists covered categories carrying a zero rate.
- Confirm your company’s status. Onshoring plan, MFN agreement, or neither. Your tier follows the company, not the shipment.
- Check country of origin, not port of departure. Origin determines whether the 15 percent, 10 percent or 100 percent rate applies.
- Rebuild landed-cost models. Any calculation made before April 2, 2026 is now wrong for covered goods.
- Review foreign trade zone and drawback positions. Covered goods entering an FTZ after the effective date must be admitted under privileged foreign status. Drawback is available on these duties.
Common Questions
Does the tariff apply to medicines I buy at a US pharmacy? Only indirectly. It is a border duty on imports, not a tax on retail sales. Whether it reaches shelf prices depends on the importer, the contract and the insurance arrangement.
Are vaccines and biologics covered? Coverage follows the HTSUS codes in Annex I. Several categories, including cell and gene therapies and plasma-derived products, are set at zero subject to conditions.
Why are some countries at 15 percent? Those rates implement pharmaceutical commitments in existing trade frameworks with the EU, Japan, South Korea, and Switzerland and Liechtenstein.
Can rates change? Yes. The proclamation lets Commerce raise rates if companies fail to meet onshoring or pricing commitments, or if partner governments fall short of their agreements.
Where This Stands
Information in this article is current as of September 5, 2026. The pharmaceutical tariff regime has changed several times since April, and the generic timeline announced in July has not yet been implemented through a proclamation. Rates, annexes and company agreements are all subject to revision.
What is unlikely to change is the design. This tariff was never built to raise revenue. It was built as leverage, and the exemption structure shows exactly what it was trading for: lower US prices on new medicines, and factories on American soil. Whether that trade delivers either is a question the next two years will answer. For readers tracking how the same instrument is being aimed at other partners, the full timeline of the tariff fight with Canada shows the pattern applied to an entire economy rather than a single sector.
